<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310400</url>
  </required_header>
  <id_info>
    <org_study_id>TG0826INF</org_study_id>
    <nct_id>NCT01310400</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children</brief_title>
  <official_title>Observer-blind, Randomized, Controlled Study to Determine the Immunogenicity and Safety of a Two-dose Regimen of Virosomal Subunit Influenza Vaccine Inflexal V in Healthy Young Children (≥6 Months to ≤35 Months) in Comparison With the Subunit Influenza Vaccine Agrippal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal
      V is as immunogenic as a locally sourced competitor vaccine in young children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity, Assessed by the Haemagglutination (HI) Test</measure>
    <time_frame>3 weeks after the 2nd vaccination</time_frame>
    <description>Seroconversion rate post-immunization. Seroconversion is defined as a post-vaccination titer of ≥1:40 for those with a pre-vaccination HI titer of &lt;1:10 and as ≥ four-fold increase in HI titer for those with a pre-vaccination HI titer of ≥1:10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fold Increase in Geometric Mean Titer (GMT)</measure>
    <time_frame>3 weeks after the 2nd vaccination</time_frame>
    <description>GMT-fold increase - calculated as the GMT on Day 49 divided by the baseline GMT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection</measure>
    <time_frame>3 weeks after the 2nd vaccination</time_frame>
    <description>Seroprotection rate, defined as a post-vaccination HI titer of 1:40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of Solicited and Unsolicited Adverse Events</measure>
    <time_frame>Solicited AEs: Days 1-4 and 28-31, and Days 28 and 49; unsolicited AEs: until study end</time_frame>
    <description>Safety assessements were made by the investigator at baseline and on Days 28 and 49, as well as by the subjects themselves (in Subjects Diaries) for the 4-day period following each vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1356</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Inflexal 0.5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Inflexal 0.25 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Agrippal 0.25 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inflexal V</intervention_name>
    <description>Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28</description>
    <arm_group_label>Inflexal 0.5 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inflexal V</intervention_name>
    <description>Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:
15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28</description>
    <arm_group_label>Inflexal 0.25 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Agrippal</intervention_name>
    <description>Agrippal influenza vaccine
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28</description>
    <arm_group_label>Agrippal 0.25 mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥6months to ≤35 months-old healthy children (male or female) born at term after normal
             pregnancy

          -  Recording of medical history and physical examination reveal no abnormality

          -  The parent/legal guardian of the participating child must sign the written informed
             consent and agree to provide a blood sample taken from the child pre- and
             post-immunization

        Exclusion criteria:

          -  Hypersensitivity to eggs, chicken proteins, polymyxin B, neomycin or any component of
             the vaccine

          -  Previous vaccination against influenza

          -  At time of enrollment, presentation of clinical symptoms of active infection and/or
             body temperature ≥38°C

          -  Confirmation or suspicion of immunosuppressed status (including cancer), or
             confirmation of immunodeficiency disease (congenital or acquired including HIV)

          -  Medical treatment (&gt;2 weeks) with immune suppressant or immune modulating drugs
             including systemic steroids during the last 3 months before immunization or at
             present, as follows: long-term oral prednisone or other equivalent steroid:
             ≥0.5mg/kg/day (note: administration of local or inhaled steroids before or during the
             study is allowed)

          -  Treatment with immunoglobulins or blood products during the last 3 months before
             immunization or such treatment scheduled during the study

          -  Participation in other clinical trials during the last 3 months before immunization or
             intention to participate during this study period

          -  At present or during the last 6 months before immunization: radiotherapy or treatment
             with cytotoxic drugs

          -  Other vaccination with a killed vaccine within 14 days before immunization or with an
             attenuated vaccine within 28 days before immunization (note: after subject inclusion
             vaccines of the immunization program for children are allowed upon the physician's
             discretion. However, immunization on the same day must be avoided)

          -  Family history of Guillain-Barré Syndrome

          -  Severe congenital deficiency or disease

          -  Antecedent of neurological disease or epileptic attack

          -  Severe cardiopulmonary disease with possibility to influence the study result

          -  Disturbance of coagulation or under anticoagulant treatment, likely to be
             contraindicated to i.m. injection

          -  Suspected non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongcheng Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Zhuang Autonomous Region CDC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangxi Zhuang Autonomous Region CDC</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530028</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2011</study_first_posted>
  <results_first_submitted>October 23, 2012</results_first_submitted>
  <results_first_submitted_qc>March 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2013</results_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Virus</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Immunisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inflexal V 0.5 mL</title>
          <description>Subjects received 2 doses: 1st dose on Day 0, 2nd dose on Day 28</description>
        </group>
        <group group_id="P2">
          <title>Inflexal V 0.25 mL</title>
          <description>Subjects received 2 doses: 1st dose on Day 0, 2nd dose on Day 28</description>
        </group>
        <group group_id="P3">
          <title>Agrippal 0.25 mL</title>
          <description>Subjects received 2 doses: 1st dose on Day 0, 2nd dose on Day 28</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="452"/>
                <participants group_id="P2" count="452"/>
                <participants group_id="P3" count="452"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="424"/>
                <participants group_id="P2" count="420"/>
                <participants group_id="P3" count="422"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inflexal V 0.5 mL</title>
          <description>The safety data are shown for the safety population (N = 452 for this group).</description>
        </group>
        <group group_id="B2">
          <title>Inflexal V 0.25 mL</title>
          <description>The safety data are shown for the safety population (N = 451 for this group).</description>
        </group>
        <group group_id="B3">
          <title>Agrippal 0.25 mL</title>
          <description>The safety data are shown for the safety population (N = 451 for this group).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="452"/>
            <count group_id="B2" value="451"/>
            <count group_id="B3" value="451"/>
            <count group_id="B4" value="1354"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="452"/>
                    <measurement group_id="B2" value="451"/>
                    <measurement group_id="B3" value="451"/>
                    <measurement group_id="B4" value="1354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="0.7"/>
                    <measurement group_id="B2" value="1.8" spread="0.7"/>
                    <measurement group_id="B3" value="1.8" spread="0.7"/>
                    <measurement group_id="B4" value="1.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="206"/>
                    <measurement group_id="B4" value="648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="452"/>
                    <measurement group_id="B2" value="451"/>
                    <measurement group_id="B3" value="451"/>
                    <measurement group_id="B4" value="1354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity, Assessed by the Haemagglutination (HI) Test</title>
        <description>Seroconversion rate post-immunization. Seroconversion is defined as a post-vaccination titer of ≥1:40 for those with a pre-vaccination HI titer of &lt;1:10 and as ≥ four-fold increase in HI titer for those with a pre-vaccination HI titer of ≥1:10.</description>
        <time_frame>3 weeks after the 2nd vaccination</time_frame>
        <population>According-to-protocol population: subjects who received both doses of influenza vaccine, with available pre- and post-vaccination titers and without major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Inflexal V 0.5 mL</title>
            <description>The immunogenicity results are shown for the per-protocol population (N = 423 for this group).</description>
          </group>
          <group group_id="O2">
            <title>Inflexal V 0.25 mL</title>
            <description>The immunogenicity results are shown for the per-protocol population (N = 380 for this group).</description>
          </group>
          <group group_id="O3">
            <title>Agrippal 0.25 mL</title>
            <description>The immunogenicity results are shown for the per-protocol population (N = 384 for this group).</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity, Assessed by the Haemagglutination (HI) Test</title>
          <description>Seroconversion rate post-immunization. Seroconversion is defined as a post-vaccination titer of ≥1:40 for those with a pre-vaccination HI titer of &lt;1:10 and as ≥ four-fold increase in HI titer for those with a pre-vaccination HI titer of ≥1:10.</description>
          <population>According-to-protocol population: subjects who received both doses of influenza vaccine, with available pre- and post-vaccination titers and without major protocol violations</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of subjects seroconverted: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="95.1" upper_limit="98.5"/>
                    <measurement group_id="O2" value="89.7" lower_limit="86.2" upper_limit="92.6"/>
                    <measurement group_id="O3" value="92.7" lower_limit="89.6" upper_limit="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroconverted: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="87.4" upper_limit="93.2"/>
                    <measurement group_id="O2" value="83.4" lower_limit="79.3" upper_limit="87.0"/>
                    <measurement group_id="O3" value="82.6" lower_limit="78.4" upper_limit="86.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroconverted: B-strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" lower_limit="52.6" upper_limit="62.2"/>
                    <measurement group_id="O2" value="47.9" lower_limit="42.8" upper_limit="53.1"/>
                    <measurement group_id="O3" value="37.2" lower_limit="32.4" upper_limit="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This statistical anaylsis evaluated the non-inferiority of 0.5 mL Inflexal V vs. 0.25 mL Agrippal for the A/H1N1 strain.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study evaluated the non-inferiority of 0.5 mL Inflexal V and 0.25 mL Inflexal V in comparison to 0.25 mL Agrippal. Seroconversion rate was the primary endpoint. The difference in seroconversion rates between each Inflexal V and the control group was used for the evaluation of non-inferiority. If the lower limit of the 95% CI of this difference was greater than -10% for all 3 strains, the Inflexal V group was considered non-inferior to the control group.</non_inferiority_desc>
            <p_value>0.0036</p_value>
            <p_value_desc>The significance level α = 0.05 (one-sided) was adjusted to α = 0.025 (one-sided) for the primary endpoint</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in seroconversion rates</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>7.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This statistical anaylsis evaluated the non-inferiority of 0.25 mL Inflexal V vs. 0.25 mL Agrippal for the A/H1N1 strain.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study evaluated the non-inferiority of 0.5 mL Inflexal V and 0.25 mL Inflexal V in comparison to 0.25 mL Agrippal. Seroconversion rate was the primary endpoint. The difference in seroconversion rates between each Inflexal V and the control group was used for the evaluation of non-inferiority. If the lower limit of the 95% CI of this difference was greater than -10% for all 3 strains, the Inflexal V group was considered non-inferior to the control group.</non_inferiority_desc>
            <p_value>0.1465</p_value>
            <p_value_desc>The significance level α = 0.05 (one-sided) was adjusted to α = 0.025 (one-sided) for the primary endpoint</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in seroconversion rates</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This statistical anaylsis evaluated the non-inferiority of 0.5 mL Inflexal V vs. 0.25 mL Agrippal for the A/H3N2 strain.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study evaluated the non-inferiority of 0.5 mL Inflexal V and 0.25 mL Inflexal V in comparison to 0.25 mL Agrippal. Seroconversion rate was the primary endpoint. The difference in seroconversion rates between each Inflexal V and the control group was used for the evaluation of non-inferiority. If the lower limit of the 95% CI of this difference was greater than -10% for all 3 strains, the Inflexal V group was considered non-inferior to the control group.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance level α = 0.05 (one-sided) was adjusted to α = 0.025 (one-sided) for the primary endpoint</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in seroconversion rates</param_type>
            <param_value>8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.3</ci_lower_limit>
            <ci_upper_limit>12.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This statistical anaylsis evaluated the non-inferiority of 0.25 mL Inflexal V vs. 0.25 mL Agrippal for the A/H3N2 strain.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study evaluated the non-inferiority of 0.5 mL Inflexal V and 0.25 mL Inflexal V in comparison to 0.25 mL Agrippal. Seroconversion rate was the primary endpoint. The difference in seroconversion rates between each Inflexal V and the control group was used for the evaluation of non-inferiority. If the lower limit of the 95% CI of this difference was greater than -10% for all 3 strains, the Inflexal V group was considered non-inferior to the control group.</non_inferiority_desc>
            <p_value>0.7493</p_value>
            <p_value_desc>The significance level α = 0.05 (one-sided) was adjusted to α = 0.025 (one-sided) for the primary endpoint</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in seroconversion rates</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This statistical anaylsis evaluated the non-inferiority of 0.5 mL Inflexal V vs. 0.25 mL Agrippal for the B-strain.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study evaluated the non-inferiority of 0.5 mL Inflexal V and 0.25 mL Inflexal V in comparison to 0.25 mL Agrippal. Seroconversion rate was the primary endpoint. The difference in seroconversion rates between each Inflexal V and the control group was used for the evaluation of non-inferiority. If the lower limit of the 95% CI of this difference was greater than -10% for all 3 strains, the Inflexal V group was considered non-inferior to the control group.</non_inferiority_desc>
            <p_value>0.0000</p_value>
            <p_value_desc>The significance level α = 0.05 (one-sided) was adjusted to α = 0.025 (one-sided) for the primary endpoint</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in seroconversion rates</param_type>
            <param_value>20.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.5</ci_lower_limit>
            <ci_upper_limit>27.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This statistical anaylsis evaluated the non-inferiority of 0.25 mL Inflexal V vs. 0.25 mL Agrippal for the B-strain.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study evaluated the non-inferiority of 0.5 mL Inflexal V and 0.25 mL Inflexal V in comparison to 0.25 mL Agrippal. Seroconversion rate was the primary endpoint. The difference in seroconversion rates between each Inflexal V and the control group was used for the evaluation of non-inferiority. If the lower limit of the 95% CI of this difference was greater than -10% for all 3 strains, the Inflexal V group was considered non-inferior to the control group.</non_inferiority_desc>
            <p_value>0.0029</p_value>
            <p_value_desc>The significance level α = 0.05 (one-sided) was adjusted to α = 0.025 (one-sided) for the primary endpoint</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in seroconversion rates</param_type>
            <param_value>10.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.7</ci_lower_limit>
            <ci_upper_limit>17.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Increase in Geometric Mean Titer (GMT)</title>
        <description>GMT-fold increase - calculated as the GMT on Day 49 divided by the baseline GMT value</description>
        <time_frame>3 weeks after the 2nd vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inflexal V 0.5 mL</title>
            <description>The immunogenicity results are shown for the per-protocol population (N = 423 for this group).</description>
          </group>
          <group group_id="O2">
            <title>Inflexal V 0.25 mL</title>
            <description>The immunogenicity results are shown for the per-protocol population (N = 380 for this group).</description>
          </group>
          <group group_id="O3">
            <title>Agrippal 0.25 mL</title>
            <description>The immunogenicity results are shown for the per-protocol population (N = 384 for this group).</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Increase in Geometric Mean Titer (GMT)</title>
          <description>GMT-fold increase - calculated as the GMT on Day 49 divided by the baseline GMT value</description>
          <units>Fold (ratio)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT fold increase from baseline: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="25.9"/>
                    <measurement group_id="O3" value="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT fold increase from baseline: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5"/>
                    <measurement group_id="O2" value="48.8"/>
                    <measurement group_id="O3" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT fold increase from baseline: B-strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="7.0"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection</title>
        <description>Seroprotection rate, defined as a post-vaccination HI titer of 1:40.</description>
        <time_frame>3 weeks after the 2nd vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inflexal V 0.5 mL</title>
            <description>The immunogenicity results are shown for the per-protocol population (N = 423 for this group).</description>
          </group>
          <group group_id="O2">
            <title>Inflexal V 0.25 mL</title>
            <description>The immunogenicity results are shown for the per-protocol population (N = 380 for this group).</description>
          </group>
          <group group_id="O3">
            <title>Agrippal 0.25 mL</title>
            <description>The immunogenicity results are shown for the per-protocol population (N = 384 for this group).</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection</title>
          <description>Seroprotection rate, defined as a post-vaccination HI titer of 1:40.</description>
          <units>percentage seroprotected subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of subjects seroprotected: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="95.7" upper_limit="98.9"/>
                    <measurement group_id="O2" value="92.1" lower_limit="88.9" upper_limit="94.6"/>
                    <measurement group_id="O3" value="93.2" lower_limit="90.2" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroprotected: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" lower_limit="88.1" upper_limit="93.8"/>
                    <measurement group_id="O2" value="84.5" lower_limit="80.4" upper_limit="88.0"/>
                    <measurement group_id="O3" value="82.8" lower_limit="78.7" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroprotected: B-strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" lower_limit="55.4" upper_limit="65.0"/>
                    <measurement group_id="O2" value="51.3" lower_limit="46.2" upper_limit="56.5"/>
                    <measurement group_id="O3" value="39.6" lower_limit="34.7" upper_limit="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Incidence of Solicited and Unsolicited Adverse Events</title>
        <description>Safety assessements were made by the investigator at baseline and on Days 28 and 49, as well as by the subjects themselves (in Subjects Diaries) for the 4-day period following each vaccination.</description>
        <time_frame>Solicited AEs: Days 1-4 and 28-31, and Days 28 and 49; unsolicited AEs: until study end</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inflexal V 0.5 mL</title>
            <description>The safety data are shown for the safety population (N = 452 for this group).</description>
          </group>
          <group group_id="O2">
            <title>Inflexal V 0.25 mL</title>
            <description>The safety data are shown for the safety population (N = 451 for this group).</description>
          </group>
          <group group_id="O3">
            <title>Agrippal 0.25 mL</title>
            <description>The safety data are shown for the safety population (N = 451 for this group).</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Incidence of Solicited and Unsolicited Adverse Events</title>
          <description>Safety assessements were made by the investigator at baseline and on Days 28 and 49, as well as by the subjects themselves (in Subjects Diaries) for the 4-day period following each vaccination.</description>
          <units>percentage of subjects with AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="451"/>
                <count group_id="O3" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with at least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="33.0"/>
                    <measurement group_id="O3" value="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least one solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="29.1"/>
                    <measurement group_id="O3" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least one unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Inflexal V 0.5 mL</title>
          <description>The safety data are shown for the safety population (N = 452 for this group).</description>
        </group>
        <group group_id="E2">
          <title>Inflexal V 0.25 mL</title>
          <description>The safety data are shown for the safety population (N = 451 for this group).</description>
        </group>
        <group group_id="E3">
          <title>Agrippal 0.25 mL</title>
          <description>The safety data are shown for the safety population (N = 451 for this group).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="452"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="451"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="452"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="451"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia (body temp. &gt;=38°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="452"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="451"/>
                <counts group_id="E3" events="38" subjects_affected="38" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="452"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="451"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="452"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="451"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release. A time period for this review is not specified in the study protocol.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs Director</name_or_title>
      <organization>Crucell Switzerland AG</organization>
      <phone>+41(0)319806111</phone>
      <email>info@crucell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

